Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo

Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo

Abstract Background Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to dem...

Full description

Bibliographic Details
Main Authors: Bo Zhou, Meng Xia, Bin Wang, Niresh Thapa, Lijuan Gan, Chaoyang Sun, Ensong Guo, Jia Huang, Yulan Lu, Hongbin Cai
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Journal of Ovarian Research
Subjects:
Ovarian cancer
Clarithromycin
Cisplatin-resistance
Combination therapy
Online Access:http://link.springer.com/article/10.1186/s13048-019-0570-9

Internet

http://link.springer.com/article/10.1186/s13048-019-0570-9

Similar Items